Search results
3 Reasons to Buy Moderna Stock
Motley Fool via Yahoo Finance· 1 day agoMerck is one of the leading oncology-focused drugmakers in the world, largely thanks to Keytruda, a medicine that has earned dozens & ...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 2 days agoThe companies are also testing the combo in patients with melanoma, non-small cell lung cancer,...
EMA CHMP supports CStone’s sugemalimab for metastatic NSCLC
Pharmaceutical Technology via Yahoo Finance· 6 days agoThe CHMP's positive opinion is based on the GEMSTONE-302 study, a multi-centre, randomised,...
Molecular Templates reports progress in cancer therapy trials By Investing.com
Investing.com· 6 days agoThe company's Chief Executive Eric Poma, PhD., highlighted the potential of MTEM's ETBs in...
A Bird’s Eye View of the Tumor Microenvironment
The Scientist· 6 days ago“One of the important things we as a field need to do is start really...
‘Whew. He didn’t say avoid Diet Coke’: Cancer doctor shares the 5 things he ‘would never do’
The Daily Dot· 4 days agoA popular oncology dietician just took her followers with her tothe grocery store to show them which...
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $66.29 Consensus Target Price from Analysts
ETF DAILY NEWS· 2 days agoOne research analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average ...
What To Know About Personalized mRNA Cancer Vaccines After Promising Trials From Moderna And Merck
Forbes· 5 days agoMerck and Moderna released “extremely impressive” positive data from a mid-stage trial of the...
Transplant in Unresectable Colorectal Liver Metastases?
Medscape· 3 days agoLiver transplant plus chemotherapy offers a potential cure for carefully selected patients with...
Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R)...
Digital Journal· 6 days agoAt a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk < ...
